Key facts
- This page summarizes Brett Kaplan's Form 4 filing for Eliem Therapeutics, Inc. (CLYM).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 26 Aug 2024, 17:47.
Brett Kaplan - 26 Aug 2024 Form 4 Insider Report for Eliem Therapeutics, Inc. (CLYM)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- CLYM
- Reported as of
- 26 Aug 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Aug 2024, 17:47:35 UTC
- Prior SEC filing
- 23 Feb 2022
- Next SEC filing
- 15 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Emily Pimblett, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brett Kaplan filed Form 4 for Eliem Therapeutics, Inc. (CLYM) on 26 Aug 2024.
Change
- Previous filing in this sequence was filed on 23 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELYM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +465,000
- Change %
- Price
- $0.000000
- Shares after
- 465,000
- Date
- 26 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 465,000
- Exercise price
- $5.95
- Footnotes
- F1
ELYM
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +77,500
- Change %
- Price
- $0.000000
- Shares after
- 77,500
- Date
- 26 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 77,500
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This option was granted on August 26, 2024 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through August 26, 2028, subject to the Reporting Person's continued service.
Footnote F2
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.
Footnote F3
The RSUs were granted on the Grant Date and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.